BioTransplant begins Phase I/II

BTRN began a Phase I/II trial of its AlloMune cancer system to treat therapy-refractory Hodgkin's and non-Hodgkin's lymphoma. AlloMune is a chimeric immune tolerance system using low dose chemotherapy...